Re-treating bleeding hereditary haemorrhagic telangiectasia with bevacizumab

Ho, Gwo Yaw; Zhong, Edward; Chern, Boris

doi:10.5694/mja13.10260

Topics

To the Editor: Symptomatic bleeding in patients with hereditary haemorrhagic telangiectasia (HHT) has been reported to respond to bevacizumab treatment. In this Journal in March 2011, Cruikshank and Chern described the successful treatment of gastric HHT with bevacizumab.1 Here, we present the result of a rechallenge with bevacizumab in the same patient.

1 Oncology Department, Redcliffe Hospital, Brisbane, QLD.
2 University of Queensland, Brisbane, QLD.

Correspondence: hogwoyaw@doctors.org.uk

Competing interests:

No relevant disclosures.

1. Cruikshank RP, Chern BW. Bevacizumab and hereditary haemorrhagic telangiectasia. Med J Aust 2011; 194: 324-325. <MJA full text>
2. Brinkerhoff BT, Poetker DM, Choong NW. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2011; 364: 688-689.
3. Brinkerhoff BT, Choong NW, Treisman JS, Poetker DM. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia. Am J Otolaryngol 2012; 33: 349-351.
4. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 360: 2143-2144.

Online responses are no longer available. Please refer to our instructions for authors page for more information.